Navigation Links
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
Date:5/19/2008

Abstract #735.

(2). Cortes, J et al. Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib intolerant Philadelphia chromosome positive CML in either chronic phase or accelerated phase. Oral presentation. American Society of Haematology Annual meeting. 2007. Abstract # 1040.

(3). Kantarjian, H et al. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome-Positive ALL. N Engl J Med. 354, no. 24 (2006).

(4). CancerBackup, Nice one - CancerBACUP welcomes decision on treatment for leukaemia

http://www.cancerbackup.org.uk/News/Mediacentre/Pressreleasesstatements /

2002/4352

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

Last accessed 28 April 2008

(5). Hochhaus, A et al. IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukaemia in Chronic Phase (CML-CP) Treated with Imatinib. Oral presentation. Blood (ASH Annual Meeting Abstracts) 2007 110: Abstract 25

Notes to editors

About Tasigna(R) (nilotinib)

Taken orally, twice daily, nilotinib works by inhibiting the proliferation of cells containing an abnormal chromosome. It does this by targeting the production of the Bcr-Abl protein, which is produced only by cells containing the abnormal Philadelphia chromosome. This protein is recognised as the key driver of the overproduction of cancer cells in patients with Ph+ CML.

Applying experience gained from the development of Glivec(R), a team of Novartis scientists created nilotinib in August 2002, just a year after the launch of Glivec(R). In preclinical studies, the medicine was able to overcome resistance resulting from Bcr-Abl kinase mutations in 32
'/>"/>

SOURCE Novartis Pharmaceuticals UK Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
2. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
3. BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University
4. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
5. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
6. SpineMark Partners With Regional Spine Leaders to Launch Its First Multisite Spine Research Organizations in Los Angeles, Denver
7. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
8. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
9. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
10. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
11. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)... Study Demonstrates microRNAs Extracted From a Sim...ctive Clinical Biomarkers for a Wide Range of ...oprietary Technology, Rosetta Genomics is Currentl...etect Colon Cancer, REHOVOT, Israel and JERSEY CI... -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader...
(Date:9/4/2008)...her Roche first in TaqMan(R) real-time PCR testing... lab, PLEASANTON, Calif., Sept. 4 /PRNewswire/ ...pproved the Roche COBAS(R) TaqMan(R) HBV Test,the...A approved in the U.S.,The test uses Roche,s real-...titis B virus DNA in a patient,s blood. Doctors ma...
(Date:9/4/2008)...tal Study Seeks to Enroll 750 Women at More Than 1...- QuatRx Pharmaceuticals, a,privately...ment and,commercialization of compounds to treat e...today announced that it has initiated a second,Pha...ets), the company,s,estrogen-free oral therapy in ...
(Date:9/4/2008)... Optimizing Patient Identification for Targe... Personalized Treatment HUNTINGTON BEACH, Calif.../ -- Agendia, a world leader in molecular cancer d...int(R), a new diagnostic test that,allows physicia... levels of,the estrogen receptor (ER), progesteron...
Breaking Medicine Technology:Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Agendia Launches TargetPrint(R) for Breast Cancer Patients 2FSU researcher lands 243 3 million grant to help smokers kick habit 7526 1FSU researcher lands 243 3 million grant to help smokers kick habit 7526 2Greater parental guidance suggested for noisy toy use 7524 1Greater parental guidance suggested for noisy toy use 7524 2New insights into the fate of antiparasitics in manure and manured soils 1456 1New insights into the fate of antiparasitics in manure and manured soils 1456 2New form of compound stimulates research on hydrogen storage 1454 1New form of compound stimulates research on hydrogen storage 1454 2New form of compound stimulates research on hydrogen storage 1454 3
...Calif.--(BUSINESS WIRE)--Apr 10, 2007 - The two mo...Fragile X and Down,syndromes, may share a common c...ity School of Medicine. The problem, a crippled,co...ciated with,autism., Although the genetics of the ...he brain seems to be the same, said Daniel Madison...
...(BUSINESS WIRE)--Apr 12, 2007 - INNOVIVE Pharmaceu...a from preclinical,studies of INNO-406, a potent o...vec-resistant or treatment-intolerant chronic,myel...n Association,for Cancer Research Annual Meeting. ...os Angeles Convention Center in Los Angeles,Calif...
Other Medicine Technology:Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 2Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 4Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting 2
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...es that not only fight cocaine and methamphetamine...ms. The study was conducted by a team of researc...at Baylor College of Medicine (BCM). As part of t...xamined the effect of the vaccines on subjects adm...
...le of detecting and measuring all known forms of h...r physicians in managing patient therapy. Abbott ...nced today that Abbott has received CE marking for...eaction) test for monitoring hepatitis B (HBV) vir...
...ial Programme for Research and Training in Tropica...trengthening and expanding research to prevent and...rategy builds on the programmes 30-year record of ...egies and enhancing research capacity in countries...
...Advisory Board for its transplantation programs. I...on of its United States (U.S.) clinical developme... and Larry Chodoff LifeCycle Pharma A/S OMX:LCP) t...Scientific Advisory Board (SAB) of experts in the ...
Other Medicine News:Health News:Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe 2Health News:Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe 3Health News:LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation 2
It provides cranial support in either prone or supine positions for premature infants and young children.
It provides cranial support in either supine or semi-sitting procedures.
The modular Doro headrest system is designed for both invasive and non-invasive applications in head and neck surgery. It can be adapted to all standard operating tables. It offers the decisive advan
Bunnel hand drill with Jacobs chuck, chuck size 4 mm.
Medicine Products: